-
A Palliative Care Model Impact on Knowledge and Attitudes
NCT06860932 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Amherst, New York
-
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of AZD0120 in Autoimmune Diseases
NCT07295847 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of the MIND Diet for Persons With Multiple Sclerosis
NCT06992115 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: New York
-
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Rochester
-
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· New York: New York
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· New York: New York, Rochester
-
Eccentric Exercise and Fatigue in Multiple Sclerosis
NCT06505421 ·
Phase: Not specified ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
Effect of Cooling on Balance Performance in Multiple Sclerosis
NCT06094855 ·
Phase: Not specified ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 ·
Phase: Phase 3 ·
Ages: 40 Years to 70 Years ·
Sex: All (male and female)
· New York: Buffalo
-
Genes and Environment in Multiple Sclerosis
NCT01353547 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
NCT06901687 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
NCT05982925 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
NCT06463743 ·
Phase: Phase 2 ·
Ages: 55 Years to 75 Years ·
Sex: All (male and female)
· New York: Buffalo
-
NYSCF Scientific Discovery Biobank
NCT06203106 ·
Phase: Not specified ·
Ages: 30 Days and older ·
Sex: All (male and female)
· New York: New York
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891 ·
Phase: Phase 4 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· New York: New York, Rochester
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: New York
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
NCT07225868 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Buffalo
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: Buffalo, New York
-
Study of COYA 302 for the Treatment of ALS
NCT07161999 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
TSC Biosample Repository and Natural History Database
NCT05676099 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· New York: New York, Rochester
-
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
NCT07497399 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· New York: New York
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Mineola, New York
-
Vancomycin Study in Multiple Sclerosis (MS)
NCT05539729 ·
Phase: Phase 1 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· New York: New York